Pharmacoeconomic Analysis of Axitinib as Second-Line Treatment for Metastatic Renal Cell Carcinoma

Abstract

Medline, PubMed, and EMBASE to identify full economic evaluations that compared different treatment strategies in postmenopausal women with primary breast cancer. Quality and modelling methodologies of included studies were assessed and summarised. Results: All the 31 included studies assessed surgery and none assessed PET as the initial treatment. Most included economic studies used a Markov model with life-time horizon and 1-year cycle length. Nine studies which included sub-group analysis for older women (over 65 years old) used similar economic models and transition states with younger women (50 to 65 years old). The key disease-related health states were disease-free, recurrence, and death. Recurrence was mostly separated into loco-regional and distant recurrence. ConClusions: This systematic review can inform the design of an economic model comparing PET with surgery as initial treatment in older women based on the following assumptions: (1) health states are applicable across age groups; (2) transition states for modelling surgery in the literature are transferable to model the same treatment for older women; (3) metastasis transition states including progression, progression-free, and death can be used to model the PET pathway. Future study will validate this model by using a longitudinal dataset of older women with primary breast cancer, and synthesize data from different data sources to populate this economic model. PCN138Cost EffECtivENEss of CEtuximab iN 1st-LiNE trEatmENt of ras WiLd-tyPE mEtastatiC CoLorECtaL CaNCEr iN sCotLaNd: a summary of thE submissioN to thE sCottish mEdiCiNEs CoNsortium objeCtives: Colorectal cancer is the third most common cancer in Scotland, with nearly 4,000 cases reported in 2011 and 5.2% increase in incidence in the previous 10 years. Recent studies have shown that a subgroup of metastatic colorectal cancer (mCRC) patients with wild-type (wt) RAS (KRAS and NRAS exons 2,3, 4) expressing tumours are likely to have enhanced response to anti-EGFR treatment compared to patients with mutant RAS exons (2,3, 4) . RAS biomarkers aid identification of the patient group that is likely to benefit the most from anti-EGFR treatment such as cetuximab and therefore allow more efficient use of NHS Scotland resources. A New Product Assessment Form was submitted to the Scottish Medicines Consortium with the aim of demonstrating the latest improved outcomes in RAS wt mCRC patients (versus KRAS wt) treated with cetuximab in combination with chemotherapy and its cost effectiveness compared to currently available treatments. Methods: A state-transition Markov cohort model was developed to simulate patient outcomes and costs for first and subsequent lines of treatment including the long-term survival after a successful curative resection of liver metastases. Results: The model estimated an incremental 0.28 life-years gained (LYG) with cetuximab + FOLFIRI compared to FOLFIRI alone and an incremental 0.32 LYG with cetuximab + FOLFOX compared to FOLFOX alone. The model was most sensitive to length...

A pharmacoeconomic analysis of ibrutinib in the treatment of mantle cell lymphoma

“…Cost-effectiveness analysis (СEA) is used to assess the cost of an effectiveness unit of the respective health care technologies being compared [11,12]. Therefore, this type of pharmacoeconomic analysis permits comparison of health care technologies not only on the basis of obtained final cost analysis values, but also using cost-effectiveness ratio calculation.…”